MGMT and lung cancer: Methylation events in plasma, specifically in CDKN2A, MGMT and RASSF1A[61], as well as in peripheral blood leukocytes [58] and lymphocytes [72,73], are promising less invasive sites for assessing lung cancer risk through measuring DNA methylation differences.